Description

ResMed’s Multi-Vector Growth Story: GLP-1 Tailwinds, Primary Care Expansion, and Digital Health!

ResMed’s financial performance in the second quarter of fiscal year 2026 offers insights into its operational strengths and market challenges. The company reported an 11% increase in headline revenue, or 9% growth on a constant currency basis, showcasing solid market performance across its global segments. The revenue of $1.42 billion is buoyed by robust growth in device and mask sales, particularly in the U.S., Canada, and Latin America, where sales grew by 11%. This revenue growth has been achieved despite being partially offset by a tougher operating environment in parts of Europe and Asia. A significant positive outcome of this quarter is ResMed’s substantial improvement in gross margin, which increased by 110 basis points year-over-year to reach 62.3%. This expansion is credited to improvements in component costs and efficiencies in manufacturing and logistics.